ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) recently experienced a significant reduction in its short interest for the month of November. As of November 15, 2024, the total short interest stood at 28,900 shares. This represents a notable decrease of 36.5% when compared to the previous month, where the short interest was recorded at 45,500 shares as of October 31, 2024. With an average trading volume of around 1,220,000 shares, the short-interest ratio is currently calculated at 0.0 days. This indicates that approximately 2.7% of ZyVersa's total stock is currently sold short.

ZyVersa Therapeutics Stock Performance

On Friday, shares of ZyVersa Therapeutics opened at $1.07. The company has observed a 1-year low of $1.03 and a 1-year high of $42.39. Over the past fifty days, the stock has maintained a simple moving average of $1.90, while the 200-day simple moving average stands at $3.13.

ZyVersa Therapeutics Company Overview

ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing products aimed at treating renal and inflammatory diseases. Its key drug development platforms include Cholesterol Efflux Mediator VAR 200, which is an injectable drug currently in Phase 2a clinical trials for various renal conditions, such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney diseases. Additionally, the company is working on the Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is still in the preclinical stage targeting a wide array of inflammatory conditions, including acute respiratory syndrome, multiple sclerosis, IgA nephropathy, pancreatic cancer, Parkinson's disease, Huntington's disease, atherosclerosis, Alzheimer’s disease, and obesity.

ZyVersa, stocks, shortinterest